$BCRX someone’s posted something like this before... but it’ll look and sound something like this 😂😇👀 RESEARCH TRIANGLE PARK, N.C., AUGUST 5, 2020 (GLOBE NEWSWIRE) — Biocryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from in Vivo trials that took place across multiple locations in Brazil, that Galidesivir was safe, provided post exposure prevention of SARS-COV-2 viral replication across a range of doses, and rapidly reduced viral loads to undetectable levels when dosed up to 72 hours after infection with SARS-COV-2 virus. The Zika PR from JUNE 10th says this, “galidesivir reduced Zika virus replication from the first dose administered without impairing the adaptive immune response that protects against subsequent infection. These data provide an encouraging foundation for studying sars cov 2, another RNA replicating virus, in this same animal species.” Give the Zika PR another read if you have the chance.. very encouraging results!!
  • 18
18 Likes